Raynaud’s Phenomenon and Sjögren’s Syndrome

  • Fredrick M. Wigley


In 1862, Maurice Raynaud published his medical school thesis in which he argued that some people have transient digital ischemia when exposed to cold temperatures. It is now recognized that skin blood flow in humans provides an important mechanism for normal thermoregulation. In fact, a normal response to cold exposure is vasoconstriction of the cutaneous blood vessels, leading to a decrease in heat loss from the body and protection against hypothermia [1].


Pulmonary Arterial Hypertension Cold Exposure Digital Ulcer Digital Ischemia Cutaneous Blood Vessel 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Charkoudian N. Skin blood flow in adult human thermoregulation: how it works, when it does not, and why. Mayo Clin Proc. 2003;78:603–12.PubMedCrossRefGoogle Scholar
  2. 2.
    Thompson-Torgerson CS, Holowatz LA, Kenney WL. Altered mechanisms of thermoregulatory vasoconstriction in aged human skin. Exerc Sport Sci Rev. 2008;36:122–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Chikura B, Moore TL, Manning JB, et al. Sparing of the thumb in Raynaud’s phenomenon. Rheumatology (Oxford). 2008;47:219–21.CrossRefGoogle Scholar
  4. 4.
    Gelber AC, Wigley FM, Stallings RY, et al. Symptoms of Raynaud’s phenomenon in an inner city African-American community: prevalence and self-reported cardiovascular comorbidity. J Clin Epidemiol. 1999;52:441–6.PubMedCrossRefGoogle Scholar
  5. 5.
    Block JA, Sequeira W. Raynaud’s phenomenon. Lancet. 2001;357:2042–8.PubMedCrossRefGoogle Scholar
  6. 6.
    Maricq HR, Carpentier PH, Weinrich MC, et al. Geographic variation in the prevalence of Raynaud’s phenomenon: Charleston, SC, USA, vs. Tarentaise, Savoie, France. J Rheumatol. 1993;20:70–6.PubMedGoogle Scholar
  7. 7.
    LeRoy EC, Medsger Jr TA. Raynaud’s phenomenon: a proposal for classification. Clin Exp Rheumatol. 1992;10:485–8.PubMedGoogle Scholar
  8. 8.
    Sharp GC, Irvin WS, May CM, et al. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases. N Engl J Med. 1976;295:1149–54.PubMedCrossRefGoogle Scholar
  9. 9.
    Tuffanelli DL, Winkelmann RK. Systemic scleroderma, a clinical study of 727 cases. Arch Dermatol. 1961;84:359–71.PubMedGoogle Scholar
  10. 10.
    Parker MD. Ribonucleoprotein antibodies: frequency and clinical significance in systemic lupus erythematosus, scleroderma, and mixed connective tissue disease. J Lab Clin Med. 1973;82:769–75.PubMedGoogle Scholar
  11. 11.
    Cohen ML, Dawkins B, Dawkins RL, et al. Clinical significance of antibodies to ribonucleoprotein. Ann Rheum Dis. 1979;38:74–8.PubMedCrossRefGoogle Scholar
  12. 12.
    Estes D, Christian CL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore). 1971;50:85–95.Google Scholar
  13. 13.
    Hochberg MC, Boyd RE, Ahearn JM, et al. Systemic lupus erythematosus: a review of clinicolaboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine (Baltimore). 1985;64:285–95.Google Scholar
  14. 14.
    Saraux A, Allain J, Guedes C, et al. Raynaud’s phenomenon in rheumatoid arthritis. Br J Rheumatol. 1996;35:752–4.PubMedCrossRefGoogle Scholar
  15. 15.
    De Angelis R, Cerioni A, Del Medico P, et al. Raynaud’s phenomenon in undifferentiated connective tissue disease (UCTD). Clin Rheumatol. 2005;24:145–51.PubMedCrossRefGoogle Scholar
  16. 16.
    Mosca M, Neri R, Bencivelli W, et al. Undifferentiated connective tissue disease: analysis of 83 patients with a minimum followup of 5 years. J Rheumatol. 2002;29:2345–9.PubMedGoogle Scholar
  17. 17.
    Youinou P, Pennec YL, Katsikis P, et al. Raynaud’s phenomenon in primary Sjögren’s syndrome. Br J Rheumatol. 1990;29:205–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Skopouli FN, Talal A, Galanopoulou V, et al. Raynaud’s phenomenon in primary Sjögren’s syndrome. J Rheumatol. 1990;17:618–20.PubMedGoogle Scholar
  19. 19.
    Kraus A, Caballero-Uribe C, Jakez J, et al. Raynaud’s phenomenon in primary Sjögren’s syndrome. Association with other extraglandular manifestations. J Rheumatol. 1992;19:1572–4.PubMedGoogle Scholar
  20. 20.
    Garcia-Carrasco M, Sisó A, Ramos-Casals M, et al. Raynaud’s phenomenon in primary Sjögren’s syndrome. Prevalence and clinical characteristics in a series of 320 patients. J Rheumatol. 2002;29:726–30.PubMedGoogle Scholar
  21. 21.
    Maricq HR, Carpentier PH, Weinrich MC, et al. Geographic variation in the prevalence of Raynaud’s phenomenon: a 5 region comparison. J Rheumatol. 1997;24:879–89.PubMedGoogle Scholar
  22. 22.
    Kraus A, Guerra-Bautista G, Espinoza G, et al. Defects of the retinal pigment epithelium in scleroderma. Br J Rheumatol. 1991;30:112–4.PubMedCrossRefGoogle Scholar
  23. 23.
    Diaz-López C, Geli C, Corominas H, et al. Are there clinical or serological differences between male and female patients with primary Sjögren’s syndrome? J Rheumatol. 2004;31:1352–5.PubMedGoogle Scholar
  24. 24.
    Steen V, Denton CP, Pope JE, et al. Digital ulcers: overt vascular disease in systemic sclerosis. Rheumatology (Oxford). 2009;48:iii19–24.CrossRefGoogle Scholar
  25. 25.
    Ramos-Casals M, Solans R, Rosas J, et al. Primary Sjögren syndrome in Spain: clinical and immunologic expression in 1010 patients. Medicine (Baltimore). 2008;87:210–9.CrossRefGoogle Scholar
  26. 26.
    Willeke P, Schlüter B, Schotte H, et al. Interferon-gamma is increased in patients with primary Sjögren’s syndrome and Raynaud’s phenomenon. Semin Arthritis Rheum. 2009;39:197–202.PubMedCrossRefGoogle Scholar
  27. 27.
    Foster H, Kelly C, Griffiths I. Raynaud’s phenomenon and primary Sjögren’s syndrome. Br J Rheumatol. 1990;29:493–4.PubMedCrossRefGoogle Scholar
  28. 28.
    Ramos-Casals M, Nardi N, Brito-Zerón P, et al. Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases. Semin Arthritis Rheum. 2006;35:312–21.PubMedCrossRefGoogle Scholar
  29. 29.
    Ramos-Casals M, Brito-Zerón P, Font J. The overlap of Sjögren’s syndrome with other ­systemic autoimmune diseases. Semin Arthritis Rheum. 2007;36:246–55.PubMedCrossRefGoogle Scholar
  30. 30.
    Manoussakis MN, Georgopoulou C, Zintzaras E, et al. Sjögren’s syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjögren’s syndrome. Arthritis Rheum. 2004;50:882–91.PubMedCrossRefGoogle Scholar
  31. 31.
    Font J, Ramos-Casals M, Cervera R, et al. Antineutrophil cytoplasmic antibodies in primary Sjögren’s syndrome: prevalence and clinical significance. Br J Rheumatol. 1998;37:1287–91.PubMedCrossRefGoogle Scholar
  32. 32.
    Hernandez-Molina G, Avila-Casado C, Cardenas-Velazquez F, et al. Similarities and differences between primary and secondary Sjögren’s syndrome. J Rheumatol. 2010;37(4):800–8.PubMedCrossRefGoogle Scholar
  33. 33.
    Kallenberg CG, Pastoor GW, Wouda AA. Antinuclear antibodies in patients with Raynaud’s phenomenon: clinical significance of anticentromere antibodies. Ann Rheum Dis. 1982;41:382–7.PubMedCrossRefGoogle Scholar
  34. 34.
    Koenig M, Joyal F, Fritzler MJ, et al. Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud’s phenomenon to systemic sclerosis: a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis. Arthritis Rheum. 2008;58:3902–12.PubMedCrossRefGoogle Scholar
  35. 35.
    Gelber AC, Pillemer SR, Baum BJ, et al. Distinct recognition of antibodies to centromere proteins in primary Sjögren’s syndrome compared with limited scleroderma. Ann Rheum Dis. 2006;65:1028–32.PubMedCrossRefGoogle Scholar
  36. 36.
    Salliot C, Gottenberg JE, Bengoufa D, et al. Anticentromere antibodies identify patients with Sjögren’s syndrome and autoimmune overlap syndrome. J Rheumatol. 2007;34:2253–8.PubMedGoogle Scholar
  37. 37.
    Katano K, Kawano M, Koni I, et al. Clinical and laboratory features of anticentromere antibody positive primary Sjögren’s syndrome. J Rheumatol. 2001;28:2238–44.PubMedGoogle Scholar
  38. 38.
    Tektonidou M, Kaskani E, Skopouli FN, et al. Microvascular abnormalities in Sjögren’s syndrome: nailfold capillaroscopy. Rheumatology. 1999;38:826–30.PubMedCrossRefGoogle Scholar
  39. 39.
    Caramaschi P, Biasi D, Carletto A, et al. Sjögren’s syndrome with anticentromere antibodies. Rev Rhum Engl Ed. 1997;64:785–8.PubMedGoogle Scholar
  40. 40.
    Bournia VK, Diamanti KD, Vlachoyiannopoulos PG, et al. Anticentromere antibody positive Sjogren’s syndrome: a retrospective descriptive analysis. Arthritis Res Ther. 2010;12(2):R47.PubMedCrossRefGoogle Scholar
  41. 41.
    Miyawaki S, Asanuma H, Nishiyama S, et al. Clinical and serological heterogeneity in patients with anticentromere antibodies. J Rheumatol. 2005;32:1488–94.PubMedGoogle Scholar
  42. 42.
    Vlachoyiannopoulos PG, Drosos AA, Wiik A, et al. Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol. 1993;32:297–301.PubMedCrossRefGoogle Scholar
  43. 43.
    Masayuki I, Kojima T, Miyata M, et al. Primary biliary cirrhosis (PBC)-CREST (Calcinosis, Raynaud’s phenomenon, esophageal dysfunction, Sclerodactyly and telangiectasia) overlap syndrome complicated by Sjögren’s syndrome and arthritis. Intern Med. 1995;34:451–4.CrossRefGoogle Scholar
  44. 44.
    Nakamura T, Higashi S, Tomoda K, et al. Primary biliary cirrhosis (PBC)-CREST overlap syndrome with coexistence of Sjögren’s syndrome and thyroid dysfunction. Clin Rheumatol. 2007;26:596–600.PubMedCrossRefGoogle Scholar
  45. 45.
    O’Keefe ST, Tsapatsaris NP, Beetham Jr WP. Association between Raynaud’s phenomenon and migraine in a random population of hospital employees. J Rheumatol. 1993;20:1187–8.Google Scholar
  46. 46.
    Pal B, Gibson C, Passmore J, et al. A study of headaches and migraine in Sjögren’s syndrome and other rheumatic disorders. Ann Rheum Dis. 1989;48:312–6.PubMedCrossRefGoogle Scholar
  47. 47.
    Gökçay F, Öder G, Çelebisoy N, et al. Headache in primary Sjögren’s syndrome: a prevalence study. Acta Neurol Scand. 2008;118:189–92.PubMedCrossRefGoogle Scholar
  48. 48.
    Hassoun PM. Pulmonary arterial hypertension complicating connective tissue diseases. Semin Respir Crit Care Med. 2009;30:429–39.PubMedCrossRefGoogle Scholar
  49. 49.
    Launay D, Hachulla E, Hatron PY, et al. Pulmonary arterial hypertension: a rare complication of primary Sjögren syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore). 2007;86:299–315.CrossRefGoogle Scholar
  50. 50.
    Vassilliou VA, Moyssakis I, Boki KA, et al. Is the heart affected in primary Sjögren’s syndrome? An echocardiographic study. Clin Exp Rheumatol. 2008;26:109–12.Google Scholar
  51. 51.
    Hassoun PM. Therapies for scleroderma-related pulmonary arterial hypertension. Expert Rev Respir Med. 2009;3:187–96.PubMedCrossRefGoogle Scholar
  52. 52.
    Abdelhady K, Gramling-Babb P, Awad S, et al. Current and future therapy for pulmonary hypertension in patients with right and left heart failure. Expert Rev Cardiovasc Ther. 2010;8:241–50.PubMedCrossRefGoogle Scholar
  53. 53.
    Pirildar T, Tikiz C, Ozkaya S, et al. Endothelial dysfunction in patients with primary Sjögren’s syndrome. Rheumatol Int. 2005;25:536–9.PubMedCrossRefGoogle Scholar
  54. 54.
    Garcia-Carrasco M, Pizcueta P, Cervera R, et al. Circulating concentrations of soluble L-selectin (CD62L) in patients with primary Sjögren’s syndrome. Ann Rheum Dis. 2000;59:297–9.PubMedCrossRefGoogle Scholar
  55. 55.
    Inaoki M, Sato S, Shimada Y, et al. Elevated serum levels of soluble L-selectin in patients with systemic sclerosis declined after intravenous injection of lipo-prostaglandin E1. J Dermatol Sci. 2001;25:78–82.PubMedCrossRefGoogle Scholar
  56. 56.
    Stafford L, Englert H, Gover J, et al. Distribution of macrovascular disease in scleroderma. Ann Rheum Dis. 1998;57:476–9.PubMedCrossRefGoogle Scholar
  57. 57.
    Allanore Y, Seror R, Chevrot A, et al. Hand vascular involvement assessed by magnetic resonance angiography in systemic sclerosis. Arthritis Rheum. 2007;56:2747–54.PubMedCrossRefGoogle Scholar
  58. 58.
    Colakoğu M, Cobankara V, Akpolat T. Effect of clonazepam on Raynaud’s phenomenon and fingertip ulcers in scleroderma. Ann Pharmacother. 2007;41:1544–7.CrossRefGoogle Scholar
  59. 59.
    Raynaud’s Treatment Study Investigators. Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon. Results from a randomized clinical trial with 1-year follow-up. Arch Intern Med. 2000;160:1101–8.CrossRefGoogle Scholar
  60. 60.
    Wigley FM, Korn JH, Csuka ME. Oral iloprost treatment in patients with Raynaud’s phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study. Arthritis Rheum. 1998;41:670–7.PubMedCrossRefGoogle Scholar
  61. 61.
    Thompson AE, Shea B, Welch V, et al. Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis. Arthritis Rheum. 2001;44:1841–7.PubMedCrossRefGoogle Scholar
  62. 62.
    Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud’s phenomenon: a meta-analysis. Rheumatology (Oxford). 2005;44:145–50.CrossRefGoogle Scholar
  63. 63.
    Rhedda A, McCans J, Willan AR, et al. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud’s phenomenon. J Rheumatol. 1985;12:724–7.PubMedGoogle Scholar
  64. 64.
    Wigley FM, Flavahan NA. Raynaud’s phenomenon. Rheum Dis Clin North Am. 1996;22:765–81.PubMedCrossRefGoogle Scholar
  65. 65.
    Harding SE, Tingey PC, Pope J, et al. Prazosin for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 1998;(2):CD000956.Google Scholar
  66. 66.
    Wise RA, Wigley FM, White B, et al. Efficacy and tolerability of a selective alpha(2 C)-adrenergic receptor blocker in recovery from cold-induced vasospasm in scleroderma patients: a single-center, double-blind, placebo-controlled, randomized crossover study. Arthritis Rheum. 2004;50:3994–4001.PubMedCrossRefGoogle Scholar
  67. 67.
    Fregene A, Ditmars D, Siddiqui A. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud’s phenomenon. J Hand Surg Am. 2009;34:446–52.PubMedCrossRefGoogle Scholar
  68. 68.
    Van Beek AL, Lim PK, Gear AJ, et al. Management of vasospastic disorders with Botulinum toxin A. Plast Reconstr Surg. 2007;119:217–26.PubMedCrossRefGoogle Scholar
  69. 69.
    Generini S, Seibold JR, Matucci-Cerinic M. Estrogens and neuropeptides in Raynaud’s phenomenon. Rheum Dis Clin North Am. 2005;31:177–86.PubMedCrossRefGoogle Scholar
  70. 70.
    Anderson ME, Moore TL, Hollis S, et al. Digital vascular response to topical glyceryl trinitrate, as measured by laser Doppler imaging, in primary Raynaud’s phenomenon and systemic sclerosis. Rheumatology (Oxford). 2002;41:324–8.CrossRefGoogle Scholar
  71. 71.
    Chung L, Shapiro L, Fiorentino D, et al. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud’s phenomenon: a randomized, controlled trial. Arthritis Rheum. 2009;60:870–7.PubMedCrossRefGoogle Scholar
  72. 72.
    Rajagopalan S, Pfenninger D, Somers E, et al. Effects of cilostazol in patients with Raynaud’s syndrome. Am J Cardiol. 2003;92:1310–5.PubMedCrossRefGoogle Scholar
  73. 73.
    Goldberg J, Diesk A. Successful treatment of Raynaud’s phenomenon with pentoxifylline. Arthritis Rheum. 1986;29:1055–6.PubMedCrossRefGoogle Scholar
  74. 74.
    Levien TL. Phosphodiesterase inhibitors in Raynaud’s phenomenon. Ann Pharmacother. 2006;40:1388–93.PubMedCrossRefGoogle Scholar
  75. 75.
    Caglayan E, Huntgeburth M, Karasch T, et al. Phosphodiesterase Type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med. 2006;166:231–3.PubMedCrossRefGoogle Scholar
  76. 76.
    Fries R, Shariat K, von Wilmowsky H, et al. Sildenafil in the treatment of Raynaud’s phenomenon resistant to vasodilatory therapy. Circulation. 2005;112:2980–5.PubMedGoogle Scholar
  77. 77.
    Schiopu E, Hsu VM, Impens AJ, et al. Randomized placebo-controlled crossover trial of tadalafil in Raynaud’s phenomenon secondary to systemic sclerosis. J Rheumatol. 2009;36:2264–8.PubMedCrossRefGoogle Scholar
  78. 78.
    Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. Ann Intern Med. 1994;120:199–206.PubMedGoogle Scholar
  79. 79.
    Pope J, Fenlon D, Thompson A, et al. Iloprost and cisaprost for Raynaud’s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev 1998;(2):CD000953.Google Scholar
  80. 80.
    Bettoni L, Geri A, Airò P, et al. Systemic sclerosis therapy with iloprost: a prospective observational study of 30 patients treated for a median of 3 years. Clin Rheumatol. 2002;21:244–50.PubMedCrossRefGoogle Scholar
  81. 81.
    Chung L, Fiorentino D. A pilot trial of Treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis. J Am Acad Dermatol. 2006;54:880–2.PubMedCrossRefGoogle Scholar
  82. 82.
    Marasini B, Massarotti M, Bottasso B, et al. Comparison between iloprost and alprostadil in the treatment of Raynaud’s phenomenon. Scand J Rheumatol. 2004;33:253–6.PubMedCrossRefGoogle Scholar
  83. 83.
    Gliddon AE, Doré CJ, Black CM, et al. Prevention of vascular damage in scleroderma and autoimmune Raynaud’s phenomenon. A multicenter, randomized, double-blind, placebo-controlled trial of the angiotensin-converting enzyme inhibitor quinapril. Arthritis Rheum. 2007;56:3837–46.PubMedCrossRefGoogle Scholar
  84. 84.
    Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud’s phenomenon and scleroderma. Clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial. Arthritis Rheum. 1999;42:2646–55.PubMedCrossRefGoogle Scholar
  85. 85.
    Wood HM, Ernst ME. Renin-angiotensin system mediators and Raynaud’s phenomenon. Ann Pharmacother. 2006;40:1998–2002.PubMedCrossRefGoogle Scholar
  86. 86.
    Coleiro B, Marshall SE, Denton CP, et al. Treatment of Raynaud’s phenomenon with the selective serotonin reuptake inhibitor fluoxetine. Rheumatology (Oxford). 2001;40:1038–43.CrossRefGoogle Scholar
  87. 87.
    Korn JH, Mayes M, Matucci Cerinic M, et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist. Arthritis Rheum. 2004;50:3985–93.PubMedCrossRefGoogle Scholar
  88. 88.
    Matucci-Cerinic M, Seibold JR. Digital ulcers and outcomes assessment in scleroderma. Rheumatology (Oxford). 2008;47 Suppl 5:v46–7.CrossRefGoogle Scholar
  89. 89.
    Kuwana M. Potential benefit of statins for vascular disease in systemic sclerosis. Curr Opin Rheumatol. 2006;18:594–600.PubMedCrossRefGoogle Scholar
  90. 90.
    Abou-Raya A, Abou-Raya S, Helmii M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud’s phenomenon and digital ulcers. J Rheumatol. 2008;35:1801–8.PubMedGoogle Scholar
  91. 91.
    Herrick AL, Matucci Cerinic M. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol. 2001;19:4–8.PubMedGoogle Scholar
  92. 92.
    Rosato E, Borghese F, Pisarri S, et al. The treatment with N-acetylcysteine of Raynaud’s phenomenon and ischemic ulcers therapy in sclerodermic patients: a prospective observational study of 50 patients. Clin Rheumatol. 2009;28:1379–84.PubMedCrossRefGoogle Scholar
  93. 93.
    Denton CP, Bunce TD, Dorado MB, et al. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud’s phenomenon. Rheumatology (Oxford). 1999;38:309–15.CrossRefGoogle Scholar
  94. 94.
    Matsumoto Y, Ueyama T, Endo M, et al. Endoscopic thoracic sympathicotomy for Raynaud’s phenomenon. J Vasc Surg. 2002;36:57–61.PubMedCrossRefGoogle Scholar
  95. 95.
    Yee AM, Hotchkiss RN, Paget SA. Adventitial stripping: a digit saving procedure in refractory Raynaud’s phenomenon. J Rheumatol. 1998;25:269–76.PubMedGoogle Scholar
  96. 96.
    Kotsis SV, Chung KC. A systematic review of the outcomes of digital sympathectomy for treatment of chronic digital ischemia. J Rheumatol. 2003;30:1788–92.PubMedGoogle Scholar
  97. 97.
    Hartzell TL, Makhni EC, Sampson C. Long-term results of periarterial sympathectomy. J Hand Surg Am. 2009;34:1454–60.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2011

Authors and Affiliations

  • Fredrick M. Wigley
    • 1
  1. 1.Department of Medicine, Division of RheumatologyJohns Hopkins UniversityBaltimoreUSA

Personalised recommendations